ALKEM LABORATORIES Financial Statement Analysis
|
||
|
The Revenues of ALKEM LABORATORIES have increased by 9.21% YoY .
The Earnings Per Share (EPS) of ALKEM LABORATORIES has increased by 82.47 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
ALKEM LABORATORIES Last 5 Annual Financial Results
[BOM: 539523|NSE : ALKEM]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹12,668 Cr | ₹11,599 Cr | ₹10,634 Cr | ₹8,865 Cr | ₹8,344 Cr |
| Expenses | ₹10,422 Cr | ₹9,990 Cr | ₹8,581 Cr | ₹6,923 Cr | ₹6,871 Cr |
| Operating Profit (Excl OI) | ₹2,245 Cr | ₹1,609 Cr | ₹2,053 Cr | ₹1,942 Cr | ₹1,473 Cr |
| Other Income | ₹311 Cr | ₹216 Cr | ₹163 Cr | ₹233 Cr | ₹104 Cr |
| Interest | ₹112 Cr | ₹107 Cr | ₹52 Cr | ₹59 Cr | ₹65 Cr |
| Depreciation | ₹299 Cr | ₹310 Cr | ₹304 Cr | ₹275 Cr | ₹253 Cr |
| Profit Before Tax | ₹2,023 Cr | ₹1,305 Cr | ₹1,844 Cr | ₹1,842 Cr | ₹1,260 Cr |
| Profit After Tax | ₹1,811 Cr | ₹1,007 Cr | ₹1,680 Cr | ₹1,618 Cr | ₹1,149 Cr |
| Consolidated Net Profit | ₹1,796 Cr | ₹984 Cr | ₹1,646 Cr | ₹1,585 Cr | ₹1,127 Cr |
| Earnings Per Share (Rs) | ₹150.21 | ₹82.32 | ₹137.65 | ₹132.58 | ₹94.28 |
| PAT Margin (%) | 9.35 | 5.61 | 11.00 | 12.34 | 9.27 |
| ROE(%) | 18.74 | 11.39 | 20.99 | 23.91 | 19.82 |
| ROCE(%) | 19.52 | 13.09 | 18.69 | 22.56 | 18.71 |
| Total Debt/Equity(x) | 0.12 | 0.14 | 0.30 | 0.23 | 0.26 |
Key Financials |
||
| Market Cap | : | ₹ 61,652.6 Cr |
| Revenue (TTM) | : | ₹ 12,756.6 Cr |
| Net Profit(TTM) | : | ₹ 2,197.5 Cr |
| EPS (TTM) | : | ₹ 183.7 |
| P/E (TTM) | : | 28.1 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ALKEM LABORATORIES | 2.2% | -4.1% | 2.6% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.6% | -2.1% | 16.5% |
| CIPLA | 3.6% | 0.2% | 2.3% |
| DR REDDYS LABORATORIES | 3% | -8.4% | 0% |
| ZYDUS LIFESCIENCES | 3.2% | -1% | 27.4% |
| DIVIS LABORATORIES | 4.3% | 6.5% | 63.9% |
| MANKIND PHARMA | -2.5% | -8% | 16.5% |
| TORRENT PHARMACEUTICALS | 2.9% | -0.5% | 19.4% |
| LUPIN | 8.2% | 0.4% | 37% |
ALKEM LABORATORIES Revenues
[BOM: 539523|NSE : ALKEM]
| Y-o-Y | 9.21 % |
| 5 Yr CAGR | 11.00 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹12,668 Cr | 9.21 | |
| Mar2023 | ₹11,599 Cr | 9.08 | |
| Mar2022 | ₹10,634 Cr | 19.96 | |
| Mar2021 | ₹8,865 Cr | 6.24 | |
| Mar2020 | ₹8,344 Cr | - | |
ALKEM LABORATORIES Operating Profit
[BOM: 539523|NSE : ALKEM]
| Y-o-Y | 39.52 % |
| 5 Yr CAGR | 11.11 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹2,245 Cr | 39.52 | |
| Mar2023 | ₹1,609 Cr | -21.60 | |
| Mar2022 | ₹2,053 Cr | 5.69 | |
| Mar2021 | ₹1,942 Cr | 31.83 | |
| Mar2020 | ₹1,473 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 27.74 % |
| 5 Yr CAGR | 0.10 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 17.73% | 27.74 | |
| Mar2023 | 13.88% | -28.08 | |
| Mar2022 | 19.3% | -11.91 | |
| Mar2021 | 21.91% | 24.07 | |
| Mar2020 | 17.66% | - | |
ALKEM LABORATORIES Profit After Tax
[BOM: 539523|NSE : ALKEM]
| Y-o-Y | 82.47 % |
| 5 Yr CAGR | 12.35 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹1,796 Cr | 82.47 | |
| Mar2023 | ₹984 Cr | -40.19 | |
| Mar2022 | ₹1,646 Cr | 3.82 | |
| Mar2021 | ₹1,585 Cr | 40.63 | |
| Mar2020 | ₹1,127 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 66.67 % |
| 5 Yr CAGR | 0.22 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 9.35 % | 66.67 | |
| Mar2023 | 5.61 % | -49.00 | |
| Mar2022 | 11 % | -10.86 | |
| Mar2021 | 12.34 % | 33.12 | |
| Mar2020 | 9.27 % | - | |
ALKEM LABORATORIES Earnings Per Share (EPS)
[BOM: 539523|NSE : ALKEM]
| Y-o-Y | 82.47 % |
| 5 Yr CAGR | 12.35 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹150 | 82.47 | |
| Mar2023 | ₹82 | -40.20 | |
| Mar2022 | ₹138 | 3.82 | |
| Mar2021 | ₹133 | 40.62 | |
| Mar2020 | ₹94 | - | |
ALKEM LABORATORIES Return on Capital Employed (ROCE)
[BOM: 539523|NSE : ALKEM]
| Y-o-Y | 49.12 % |
| 5 Yr CAGR | 1.07 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 19.52% | 49.12 | |
| Mar2023 | 13.09% | -29.96 | |
| Mar2022 | 18.69% | -17.15 | |
| Mar2021 | 22.56% | 20.58 | |
| Mar2020 | 18.71% | - | |
ALKEM LABORATORIES Share Price vs Sensex
| Current Share Price | : | ₹5,154.9 |
| Current MarketCap | : | ₹ 61,652.6 Cr |
| Updated EOD on | : | Feb 07,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ALKEM LABORATORIES | 2.2% |
-4.1% |
2.6% |
| SENSEX | 0.5% |
0.3% |
7.9% |
ALKEM LABORATORIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE HEALTHCARE | 3.1% | -3.6% | 24.4% |
| S&P BSE ALLCAP | 0.5% | -2.8% | 9% |
| S&P BSE MID CAP | 0.4% | -4.8% | 9.4% |
| S&P BSE LARGE MIDCAP | 0.3% | -1.2% | 7.6% |
| S&P BSE 400 MIDSMALLCAP | 0.3% | -5.2% | 8.5% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY PHARMA | 3.5% | -3.5% | 19.4% |
| NIFTY HEALTHCARE | 3.2% | -3.4% | 21.5% |
| NIFTY MIDCAP 50 | 0.6% | -3.6% | 8.3% |
| NIFTY MID SMALL400 | 0.3% | -5.2% | 7.8% |
| NIFTY500 MULTICAP 50:25:25 | 0.3% | -3% | 7.8% |
You may also like the below Video Courses
FAQ about ALKEM LABORATORIES Financials
How the annual revenues of ALKEM LABORATORIES have changed ?
The Revenues of ALKEM LABORATORIES have increased by 9.21% YoY .
How the Earnings per Share (EPS) of ALKEM LABORATORIES have changed?
The Earnings Per Share (EPS) of ALKEM LABORATORIES has increased by 82.47 % YoY .
Check out Intrinsic Value of Peers of ALKEM LABORATORIES
Compare Stock Analytics of Peers of ALKEM LABORATORIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
